Introduction A proprietary brand name can accelerate a global launch or quietly derail it. Across the US, EU, and Japan, regulators evaluate brand names not as marketing assets, but as patient‑safety controls. Differences in legal frameworks, linguistic expectations, and review timing mean that a name acceptable in one region may face rejection in another, often [...]